Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Mirabegron. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB3 known ✓ | P13945 | 18/20 | 0.98 |
| ▸ | ADRB1 | P08588 | 7/20 | 0.80 |
| ▸ | ADRB2 | P07550 | 7/20 | 0.80 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.56 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.56 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.56 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Mirabegron SCHEMBL15993769 | 1.00 | ADRB3 (0.98) | ADRB3ADRB1ADRB2CYP2D6SLC6A4 | |
| Mirabegron SCHEMBL15993771 | 1.00 | ADRB3 (0.98) | ADRB3ADRB1ADRB2CYP2D6SLC6A4 | |
| Mirabegron SCHEMBL1405678 | 1.00 | ADRB3 (0.98) | ADRB3ADRB1ADRB2CYP2D6SLC6A4 | |
| Mirabegron SCHEMBL904789 | 0.99 | ADRB3 (1.00) | ADRB3ADRB1ADRB2CYP2D6SLC6A4 | |
| Mirabegron SCHEMBL805237 | 0.99 | ADRB3 (1.00) | ADRB3ADRB1ADRB2CYP2D6SLC6A4 | |
| Mirabegron SCHEMBL904788 | 0.99 | ADRB3 (1.00) | ADRB3ADRB1ADRB2CYP2D6SLC6A4 | |
| Mirabegron SCHEMBL16611070 | 0.96 | ADRB3 (0.94) | ADRB3ADRB1ADRB2CYP2D6SLC6A4 | |
| SCHEMBL16609366 | 0.89 | ADRB3 (0.81) | ADRB3ADRB1ADRB2CYP2D6SLC6A4 | |
| Hydrochloric Acid SCHEMBL6622281 | 0.89 | ADRB3 (0.80) | ADRB3ADRB1ADRB2 | |
| SCHEMBL16609248 | 0.89 | ADRB3 (0.81) | ADRB3ADRB1ADRB2CYP2D6SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2298752-B1 | Alpha-form or beta-form crystal of acetanilide derivative | ASTELLAS PHARMA INC (JP) | 2013-03-27 | — | — | EP | disclosed |
| US-7982049-B2 | (R)-2-(2-aminothiazol-4-yl)-4'-[2-[(2-hydroxy-2-phenylethyl)amino]ethyl]acetanilide and a carrier; diabetes, anti-obesity and anti-hyperlipemia | ASTELLAS PHARMA INC. (JP) | 2011-07-19 | — | — | US | disclosed |
| EP-2298752-A1 | Alpha-form or beta-form crystal of acetanilide derivative | Astellas Pharma Inc. (JP) | 2011-03-23 | — | — | EP | disclosed |
| US-20080214633-A1 | Alpha-form or beta-form crystal of acetanilide derivative | ASTELLAS PHARMA INC. | 2008-09-04 | — | — | US | disclosed |
| EP-1932838-A2 | Beta-form crystal of acetanilide derivative | Astellas Pharma Inc. (JP) | 2008-06-18 | — | — | EP | disclosed |
| US-7342117-B2 | (R)-2-(2-aminothiazol-4-yl)-4'-[2-[(2-hydroxy-2-phenylethyl)amino]ethyl]-acetanilide; free base forms; stability; moisture resistance | ASTELLAS PHARMA INC. (JP) | 2008-03-11 | — | — | US | disclosed |
| US-20050004190-A1 | Alpha-form or beta-form crystal of acetanilide derivative | ASTELLAS PHARMA INC. (JP) | 2005-01-06 | — | — | US | disclosed |
| EP-1440969-A1 | ALPHA-FORM OR BETA-FORM CRYSTAL OF ACETANILIDE DERIVATIVE | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2004-07-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004190-A1 | Alpha-form or beta-form crystal of acetanilide derivative | IAPP, AMY1A, AMY2A | ADRB3 635/4885ADRB1 223/4885ADRB2 329/4885 |
| US-20080214633-A1 | Alpha-form or beta-form crystal of acetanilide derivative | IAPP, AMY1A, AMY2A | ADRB3 760/4885ADRB1 249/4885ADRB2 351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.